Drug Trial Radar · NCT07811726
A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
Feb 28, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- NexThera Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2 trial is a randomized, double-blind, placebo-controlled, multicenter study in patients with wet AMD to assess the efficacy and safety of NT-101 topical ophthalmic solution (0.20 mM) administered into the study eye twice daily (BID) for 12 weeks.
Conditions
- Wet Age Related Macular Degeneration
Interventions
NT-101 ophthalmic solutionDrug
NT-101 is a topical ophthalmic solution containing pigment epithelium-derived factor (PEDF) 34 and type I atelocollagen
PlaceboDrug
NT-101 without Drug Substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA in the study eye at Week 12 compared to baselineTime frame: Week 12 compared to baseline
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Advanced Retina Institute
Bonita Springs, Florida · Recruiting
Tulsa Retina Consultants
Tulsa, Oklahoma · Recruiting
Erie Retina Research
Erie, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.